The Eye Drink is a ready-to-drink functional beverage formulated specifically for ocular health — science-backed, AREDS 2-based nutrition in a refreshing, vegan-friendly drink built for today’s screen-heavy world.
Created by optometrist Dr. Roger L. Wu and co-developed with ophthalmologist Dr. Garlan Lo. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
1st
Ready-to-drink beverage made for eye health
0%
Up to this much real fruit juice
0+
Bottles/month at a single optometry practice
0+
Years of founder eye-care experience
The Problem
Screens are everywhere — and our eyes are paying the price
Work, school and leisure now run on screens. Prolonged screen time drives a rise in dry eye, digital eye strain and exposure to high-energy blue light — increasingly even in younger patients.
Yet the most common eye-health solutions are pills and gel caps that many people simply don’t like to take. That compliance gap — people who stop taking supplements they dislike — is exactly the problem The Eye Drink was built to solve.
A solution for eyes in a digital world
The Solution
Doctor-developed nutrition in a drink you’ll actually finish
Each 16.9 fl oz bottle delivers clinically informed, AREDS 2-based eye nutrition in a refreshing format — up to 50% real fruit juice, vegan-friendly, and easy to drink every day.
Relieves dry, tired eyes
Hydrating agents and fruit extracts help soothe discomfort from long screen days.
Supports macular & long-term eye health
AREDS 2 carotenoids and antioxidants support the macula and tear quality.
Scientifically formulated
A proprietary, doctor-developed formula — not a generic supplement.
The Science
Built on the AREDS 2 formulation
The Eye Drink is based on the AREDS 2 nutrient profile — nutrients studied for their role in eye health — delivered in beverage form. In the Company’s testing, the juice format showed faster nutrient absorption than AREDS 2 gel caps, even at a fraction of the dose.
Omega-3 (EPA & DHA) from algae
Vegan-friendly, to help reduce inflammation
Lutein & zeaxanthin
Carotenoids that support macular health
Vitamins C & E
Antioxidants that help fight oxidative stress
Zinc
An essential mineral in the AREDS 2 profile
Hydrating agents & fruit extracts
Up to 50% real juice — to combat dryness and taste great
These statements have not been evaluated by the U.S. Food and Drug Administration. The product is not intended to diagnose, treat, cure or prevent any disease.
The Product
Three refreshing flavors
Made to taste like a treat, not a supplement — so it’s easy to make eye health part of every day.
Magical Citrus
Bright, zesty and refreshing
50% juice
Strawberry Lemonade
Sweet, tart and crowd-pleasing
47% juice
Mango Strawberry
Tropical and smooth — the newest flavor
47% juice
Why It’s Different
A first-mover with a real edge
First of its kind
What the Company believes to be the first ready-to-drink functional beverage formulated specifically for ocular health.
Doctor-developed & credible
Created by eye-care professionals and recommended through optometry & ophthalmology offices.
Solves a compliance gap
A palatable, easy alternative to pills — the format people will actually keep using day after day.
Go-To-Market
Three channels driving repeat revenue
1
Eye-care professional channel
Recommended and sold through optometry and ophthalmology offices. The Company reports solo practices selling roughly 550–850 bottles per month, at margins it believes exceed most traditional nutraceuticals.
2
Direct-to-consumer
E-commerce sales through theeyedrink.com — single bottles and 12-packs.
3
Subscription — “The Eye Drink Club”
Recurring monthly delivery for predictable, repeat revenue, plus planned expansion into complementary retail & wellness channels.
Traction
The professional channel is the wedge
When an eye doctor recommends a product chairside, patients trust it — a credible, differentiated route to market that big supplement brands can’t easily replicate.
550–850 bottles / month
reported sell-through at a single solo optometry practice — the model the Company aims to scale across many more offices.
Market Opportunity
At the intersection of two growing categories
The Eye Drink sits where functional beverages meet eye-health nutraceuticals — both large, growing categories propelled by ever-rising screen time and the dry-eye and digital-eye-strain complaints that follow.
Functional beverages
One of the fastest-growing consumer categories as shoppers seek drinks that do more than refresh.
Eye-health nutraceuticals
Driven by aging demographics and a younger, screen-heavy generation developing eye-strain symptoms earlier.
Dr. Roger L. Wu, O.D.
The Founder
Dr. Roger L. Wu, O.D.
Founder, CEO & President
An optometrist and serial entrepreneur with more than 25 years of experience (practicing since 1997), Dr. Wu has pioneered innovations in eye care — including AI software to monitor digital-eye-strain risk factors. He holds a B.S. in Biochemistry from Rutgers University and a Doctor of Optometry from the Pennsylvania College of Optometry.
Over two decades he observed a troubling rise in dry-eye cases and early macular changes among screen-heavy patients — and a lack of solutions patients would actually stick with. He created The Eye Drink in response, co-developing the formula with ophthalmologist Dr. Garlan Lo.
At the maximum raise, net proceeds are put to work scaling production and demand. The allocation is flexible and may be adjusted by management based on the actual amount raised.
Allocation shown at the maximum offering amount (net of the 5% intermediary fee).
Inventory & Production$60,000
Sales & Marketing / Brand$40,000
Working Capital & Reserves$17,800
Financial Snapshot
FY2025 at a glance
Year ended December 31, 2025 — the first period reflecting the Company’s official launch.
$13,688
Cash & equivalents
$67,839
Total assets
$58,599
Stockholders’ equity
$2,911
Net revenue (FY2025)
$(163,829)
Net loss
$337,015
Founder capital invested to date
All figures are unaudited and stated in U.S. dollars. See the Company’s Form C and financial statements for full detail and important assumptions.
The Offering
Key terms
Security typeCommon Stock
Price per share$4.25
Pre-money valuation$16,335,003
RegulationReg CF
Min / Max raise$1,003 / $124,000
Closing dateDec 31, 2026
About The Eye Drink
The Eye Drink is developed and sold by 20Slash20, Inc., a Delaware corporation headquartered in West Covina, California. The Eye Drink is a functional beverage / dietary supplement. Statements regarding its benefits have not been evaluated by the U.S. Food and Drug Administration, and the product is not intended to diagnose, treat, cure or prevent any disease.
Product Performance Statements
Statements about absorption, sell-through and per-practice volumes reflect the Company’s own observations and testing and are not independently verified. Individual results may vary.
Forward-Looking Statements
This page contains forward-looking statements within the meaning of the federal securities laws — including statements using terms such as “anticipate,” “expect,” “intend,” “may,” “will” and “should.” These involve risks and uncertainties that could cause actual results to differ materially from those expressed. Financial figures are unaudited.
An investment in this offering is speculative and involves a high degree of risk, including the possible loss of your entire investment. The shares are illiquid, the valuation was set by management without an independent appraisal, and investors will hold a minority position with voting rights delegated by proxy to the CEO. Please review the Company’s Form C, including the Risk Factors, in full before investing.
Note:
The information provided is a summary only. Please review the full offering documents (Form C) for a full description of the company and offering.
You can cancel an investment commitment until 48 hours prior to the offering deadline.
$0
of target $1,003 - $124,000
0% funded
to go
Minimum Target
$1,003
Maximum Target
$124,000
Pre-money Valuation
$16,335,003
Equity Offered
0.01% - 0.75%
Securities Type
Common Stock
Regulation
Regulation CF
Closing Date
31 Dec 2026
Share Price
$4.25
Shares Offered
236 - 29,176.4
Shares Issued After Offering
3,843,766 - 3,872,706.4
Corporate Profile:
Company Name
20Slash20, Inc.
Jurisdiction of Incorporation
Delaware
Date of Incorporation
16 Mar 2023
Telephone
Address
2707 E Valley Blvd #216 West Covina California 91792 United States
IMPORTANT LEGAL NOTICE: Ksdaq Inc. owns and operates Mr. Crowd (www.MrCrowd.com), a funding portal (the "Funding Portal") registered with the Securities and Exchange Commission (SEC) and a member of the Financial Industry Regulatory Authority (FINRA) [FINRA Funding Portal Members]. By accessing the Funding Portal and any pages on the Funding Portal, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time without notice or liability.
Securities offerings posted on the Funding Portal are limited to Regulation Crowdfunding offerings.
Investors must acknowledge and accept the high risks associated with investing in private securities offerings. These risks include holding your investment for periods of many years with limited ability to resell, limited access to periodic reporting, and losing your entire investment. You must have the ability to bear a total loss of your investment without a change in your lifestyle. Funding Portal is only required to conduct limited due diligence on each Issuer and does not in any way give investment advice, provide analysis or recommendations regarding any offering posted on the Funding Portal. Past performance is not indicative of future performance. All investors should make their own determination of whether or not to make any investment in an offering, based on their own independent evaluation and analysis and after consulting with their financial, tax and investment advisors. Prior to making any investment, you will be required to demonstrate your understanding of the speculative nature of investing in such private securities. The securities offered on this Funding Portal can only be marketed in jurisdictions where public solicitation of offerings are permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence. You are strongly advised to consult your legal, tax and financial advisor before investing.
You can learn more about investing in crowdfunding from the SEC,
FINRA or
NASAA.
West Covina, California 
Healthcare 
Portfolio
Watchlist
My Account
Logout
West Covina, California
Healthcare
Important: 
Note:
